DAY 5

Longevity: Cardiovascular Health
CAC, Lp(a), BP Targets, HRV

2026-05-26 · BigCat's Vitality Protocol

Evidence base: RCTs (SPRINT, JUPITER) + Mendelian randomization (Lp(a)) + large prospective cohorts (MESA, FHS) + Attia "Medicine 3.0" consensus

SUB · Imaging Screen / Primary Prevention

Coronary Artery Calcium (CAC) — Seeing Plaque Before It Speaks

ONE-LINE TAKEAWAY

A ~$50 low-dose CT scan (~1 mSv) upgrades CV risk prediction by an order of magnitude. CAC = 0 nearly rules out MI within 5 years; CAC ≥ 100 means "start statin now," regardless of how "normal" LDL-C looks.

EVIDENCE

Large prospective cohorts: MESA (Detrano 2008 NEJM, 6,800 subjects) established CAC's independent predictive power, with net reclassification superior to standard risk scores. Budoff 2018 (JACC) 15-year follow-up: all-cause mortality 5× lower in CAC=0 vs CAC>400. ACC/AHA 2018/2019 primary prevention guidelines formally incorporated CAC for "borderline/intermediate risk" decisions. CONFIRM registry (>30,000) confirmed cross-population consistency.

SCIENCE + MECHANISM

CAC directly quantifies calcified plaque volume in coronary arteries (Agatston score) — imaging evidence that atherosclerosis has already happened. Traditional risk scores (Framingham, ASCVD Pooled Cohort) estimate population probabilities; CAC measures your actual pathological burden — are you on the average curve or already off it? Calcification marks plaque maturation (lipid pool → fibrous cap → calcification), reflecting both past cumulative exposure and predicting future event rates. CAC=0 is the famous "power of zero": in low-to-intermediate-risk populations, 10-year event rates run <1%, allowing more permissive statin decisions (but not for those <45, where plaque may not yet have calcified).

VISUALIZATION: CAC Score and Risk Stratification

CAC is a "time microscope" — it converts statistical probability into a concrete number inside your arteries.

PROTOCOL

Who should get it:
• Men ≥40, women ≥45 with "borderline" or "intermediate" traditional risk
• Any age with premature CV family history (1st-degree relative: M <55, F <65)
• Lp(a) ≥ 50 mg/dL / diabetes / autoimmune disease / HIV

How:
• Low-dose gated chest CT, no contrast, <10 sec scan, 0.7–1.0 mSv (≈ one trans-Pacific flight)
• Cost ~$50–150 in many markets; available at cardiology/imaging departments
• Result = Agatston score + age/sex percentile (where you sit among same-age, same-sex peers)

How to use the result:
• CAC = 0, few risk factors: may defer statin, recheck in 5 years (excludes <45)
• CAC 1–99: low-to-moderate statin + strict ApoB target <80
• CAC ≥ 100 OR ≥ 75th percentile for age: treat as high-risk; ApoB <60, statin ± ezetimibe
• Repeat interval: CAC=0 → 5 years; CAC>0 → no need to chase serial scans (treatment goal is ApoB, not slowing the calcium number)

FEMALE-SPECIFIC NOTE + COMMON MYTHS

Women's CAC appears 7–10 years later than men's; CAC=0 is common premenopause, but post-menopausal ApoB drift accelerates calcification. SWAN imaging substudy: the menopausal transition is a key window of "asymptomatic coronary calcification onset." A given CAC score in women is more ominous than the same score in men (Shaw 2008 JACC — same score, women have higher relative MI/death risk). MESA data: women at or above the 75th percentile for age should seriously consider statins regardless of perceived symptom-free status.

Myth 1: "High CAC means statins are too late" — opposite: statins stabilize plaque (reduce lipid core, thicken fibrous cap), cutting events 25–35% (FOURIER) even when the calcium number doesn't decrease.
Myth 2: "CAC=0 means I can relax about diet" — CAC reflects the past, not the future. Lp(a), ApoB, lifestyle still determine new plaque over the next 10 years.
Myth 3: "Young people don't need it" — <45 sensitivity is low (soft plaque uncalcified); CCTA or ApoB/Lp(a) are better tools.

THIS WEEK + REFLECTION

THIS WEEK

Look up local availability and pricing of "coronary calcium scan" / "cardiac CT calcium score" at major hospitals or imaging centers. If you fit the "who should get it" criteria, schedule it at your next annual checkup (no fasting, <30 min).

Reflection: A traditional risk score gives a probability (e.g., 8%); CAC gives a concrete number (e.g., 47). The former is "population"; the latter is "you." Are you willing to spend 1 mSv and a small fee to see yourself more clearly?

SUB · Genetic Lipoprotein / Lifetime Risk

Lp(a) — The One-Time Genetic Test Most People Skip

ONE-LINE TAKEAWAY

Lp(a) is a genetically determined, diet/exercise-resistant independent causal driver of ASCVD. ~20% of the global population is elevated (≥ 50 mg/dL), doubling MI, aortic stenosis, and ischemic stroke risk. Test it once in a lifetime — yet most clinicians don't order it.

EVIDENCE

Mendelian randomization (top causal evidence): Kamstrup 2009 (JAMA) and Burgess 2018 (JAMA Cardiol) used LPA gene variants to establish Lp(a) as causal for MI and valve calcification. EAS 2022 consensus (Kronenberg, Eur Heart J): all adults should be measured once in life. UK Biobank (460,000): top Lp(a) quintile carries ~2× MI risk independent of LDL-C. The HORIZON trial (pelacarsen, antisense oligonucleotide) is the first RCT to test directly lowering Lp(a) on hard CV outcomes (results 2025).

SCIENCE + MECHANISM

Lp(a) = an LDL particle plus a covalently attached apo(a) protein. apo(a) structurally resembles plasminogen → interferes with fibrinolysis → prothrombotic. It also carries oxidized phospholipids (OxPL) → strongly proinflammatory/atherogenic. LPA gene determines 70–90% of plasma Lp(a); the level is roughly fixed from birth (±20%), barely moved by diet/exercise/statin (statins even slightly increase it). It is the most-missed high-risk marker in otherwise asymptomatic adults. East Asians average lower Lp(a) than Europeans, but 10–15% are still elevated — "Asians don't need it" is not a safe assumption.

PROTOCOL

Lp(a) (mg/dL)	Risk tier	Action
< 30	Low	Standard management; no retesting required for life
30–49	Borderline	Tighten other modifiables (ApoB <80, BP <120/80)
50–99	Elevated	ApoB target <60; consider baseline CAC + carotid US
≥ 100	Markedly elevated	ApoB <50; aggressive primary prevention; screen first-degree relatives
≥ 180 (or >430 nmol/L)	Extreme	Treat as secondary prevention; PCSK9i lowers ~25–30%; watch pelacarsen pipeline

• Units: mg/dL and nmol/L are not directly convertible (particle size variability) — prefer nmol/L when available
• Simple blood test, no fasting required
• One test for life suffices (unless reassessing after treatment); store in family health record
• If ≥ 50 mg/dL: alert first-degree relatives (70% heritable)
• Current Lp(a)-lowering options: statins 0%/slight rise; niacin 20–25% (abandoned, side effects); PCSK9i 25–30%; antisense (pelacarsen/olpasiran) 80%+ (Phase III)

FEMALE-SPECIFIC NOTE + COMMON MYTHS

Elevated Lp(a) in women is associated with higher rates of preeclampsia and recurrent miscarriage — preconception testing has family-planning value. Lp(a) rises slightly post-menopause (10–15%), but remains primarily genetic. SWAN and WHI data: women with high Lp(a) experience accelerated ASCVD across the menopausal transition; assess during perimenopause, not years later. MHT has neutral-to-mildly-lowering effects on Lp(a) and should not be used as Lp(a) therapy.

Myth 1: "Lp(a) is fixed, so testing is pointless" — you can't change the gene, but you can drive every modifiable factor (ApoB, BP, smoking, body composition) harder, pushing the plaque clock back 10–20 years.
Myth 2: "Statins lower Lp(a)" — basically not; some studies show slight elevation. Statin's value is ApoB reduction; Lp(a) needs a dedicated plan.
Myth 3: "Lp(a) is rare in Asians" — average is lower but the distribution overlaps; skipping the test is rolling dice.

THIS WEEK + REFLECTION

THIS WEEK

Add Lp(a) (lipoprotein-a) to your next blood draw. Most routine panels exclude it — request explicitly. One test, lifetime answer. File it alongside ApoB and CAC in your long-term health record.

Reflection: If your Lp(a) is 80 mg/dL (your parents likely too), would you tell your child to test after age 18? What's the ethical/psychological weight of "unchangeable" genetic information?

SUB · Blood Pressure / Primary Prevention

Blood Pressure Targets — Recalibrating "Normal 120/80" to "Optimal 110/70"

ONE-LINE TAKEAWAY

Post-SPRINT, BP targets shifted from <140/90 to <130/80 (ACC/AHA 2017), but the longevity-optimal target is ≤ 120/80 (office) or ≤ 115/75 (home/ABPM). One-shot office readings are polluted by white-coat effect and measurement error — home BP + ABPM are more accurate and better predict hard endpoints.

EVIDENCE

Landmark RCT: SPRINT 2015 (NEJM, 9,361 subjects) — intensive BP control (SBP target <120 vs <140) cut CV events 25%, all-cause mortality 27%, terminated 1 year early. STEP 2021 (NEJM, 8,500 elderly Chinese) replicated. Meta-analysis Ettehad 2016 (Lancet, 123 RCTs, 613,000): every 10 mmHg SBP drop → 20% MACE, 13% mortality reduction. Home/ABPM superior to office: Sega 2005 PAMELA, Hansen 2007 IDACO cohorts.

SCIENCE + MECHANISM

Blood pressure is pressure × time of exposure: arterial walls bear mechanical stress → endothelial dysfunction → easier ApoB-particle entry → accelerated atherosclerosis. High pressure also raises cardiac afterload → LV hypertrophy → diastolic dysfunction → atrial fibrillation, HFpEF. Nighttime BP is the strongest mortality predictor (Hansen 2011) — normal subjects "dip" ≥10% at night; "non-dippers" independently predict CV death. Single office readings carry large error; white-coat effect can inflate by 10–20 mmHg, but "masked hypertension" goes the other way — normal office, elevated home/night, even more dangerous. Home BP and 24h ABPM are the gold standards.

VISUALIZATION: Office vs Home vs ABPM Thresholds

"Office 130" ≠ "true 130." Most people are overestimated 5–15 mmHg in clinic; a minority are "masked" the other way — only home/ABPM separates them.

PROTOCOL

Measurement (the most-skipped piece):
• Upper-arm electronic monitor (wrist devices unreliable), CE/FDA-validated
• Sit quietly 5 min, back supported, feet flat, cuff at heart level
• Take 2–3 readings 1 min apart; average the last two
• Morning + evening, 7 consecutive days → average of last 6 days (discard day 1)

Targets (longevity-optimal, not disease thresholds):
• Office: ≤ 120/80
• Home mean: ≤ 115/75
• 24h ABPM mean: ≤ 115/75; nighttime mean: < 110/65
• Elderly (≥75) SPRINT subgroup: intensive control still benefits but fall risk slightly up — individualize

Non-pharmacologic → pharmacologic ladder:
• Zone 2 aerobic 150 min/wk → SBP −5–8 mmHg
• Sodium < 2300 mg/d (DASH) → SBP −5–6 mmHg
• Weight loss 1 kg → SBP −1 mmHg
• Alcohol < 1 drink/d → SBP −3–4 mmHg
• First-line drugs: ACEi/ARB + CCB (Asian populations respond more strongly to CCBs) + thiazide diuretic; β-blockers reserved for AFib/CAD, not first-line for HTN

FEMALE-SPECIFIC NOTE + COMMON MYTHS

Gestational hypertension and preeclampsia substantially raise future ASCVD (2–4×), HFpEF (4×), and stroke risk (Bellamy 2007 BMJ; Wu 2017 Circulation) — yet are routinely under-monitored postpartum. Establish annual BP tracking within 5 years post-delivery. The perimenopausal estrogen drop reduces vascular compliance and accelerates SBP rise; women's average SBP overtakes men's after age 50, often masked by the "I always had low BP" mental model. Oral contraceptives raise SBP ~2–4 mmHg on average (more in salt-sensitive responders) — get a baseline before starting. HFpEF skews female and older; intensive BP control is one of the few evidence-based primary preventions.

Myth 1: "Slightly elevated BP is fine, no need to treat" — pre-SPRINT "standard" arms left huge populations at "normal but suboptimal," with 25% more CV events.
Myth 2: "Office readings are enough" — 15–30% are white-coat (overestimated), 10–15% are masked (underestimated). Not measuring at home = guessing.
Myth 3: "Young people with BP 130 needn't worry" — SPRINT subgroups + Mendelian randomization show lifetime cumulative exposure is linearly damaging. Earlier control = better.

THIS WEEK + REFLECTION

THIS WEEK

Buy an upper-arm electronic BP monitor (Omron, ~$30–60). Measure morning + evening for 7 days. The average of the last 6 days is your real baseline — more useful than any office number. If home mean > 125/80, discuss lifestyle + medication options with your doctor.

Reflection: Are you willing to file "home mean" rather than "office single reading" as your long-term BP record? What does shifting data ownership to yourself actually mean?

SUB · Autonomic Function / CV Resilience

Heart Rate Variability — The Autonomic Nervous System's Battery Gauge

ONE-LINE TAKEAWAY

HRV reflects parasympathetic tone and autonomic flexibility. Higher HRV = more "flexible" autonomic nervous system. It is not diagnostic, but as a within-individual trend, it's the cheapest, most continuous monitor of CV health + training recovery + stress. Absolute values do not compare across people.

EVIDENCE

Large cohorts: Tsuji 1996 (Circulation, Framingham) and Dekker 2000 (Circulation, ARIC) — low HRV independently predicts all-cause + CV mortality. Thayer 2010 (Int J Cardiol) review: HRV correlates with BP, inflammation, glucose, cognition. Sports-science RCTs (Plews 2013, Stanley 2013 Sports Med): morning-HRV-guided training improves VO2max and performance vs fixed plans; flags overtraining/viral prodrome. Clinical evidence tier is below ApoB/BP — no RCT yet shows "raise HRV" → improved hard outcomes — so use it as a trend monitor, not a target.

SCIENCE + MECHANISM

Heart rate is not metronomic. Tiny beat-to-beat (R-R interval) variation reflects the autonomic "tug-of-war": vagal withdrawal on inhale (HR↑), vagal engagement on exhale (HR↓) — known as respiratory sinus arrhythmia (RSA), the core expression of parasympathetic tone. Common metrics: RMSSD (root mean square of successive R-R differences, mostly parasympathetic) and SDNN (total variability). Low HRV = sympathetic dominance/parasympathetic suppression = the shared phenotype of chronic stress, overtraining, infection prodrome, and worse CV outcomes — your heart's ability to "soften" when your vasculature asks. HRV is highly individual: genetics + age + sex + training state set the baseline. Don't compare across people — only against your own rolling mean.

VISUALIZATION: What Affects HRV

HRV is the low-noise earbud for your real internal state — not a diagnosis, but a few-day head-start telling you "don't push today."

PROTOCOL

How to measure:
• Tools: Whoop / Oura / Garmin / Polar H10 + Elite HRV / Apple Watch (nightly mean is most stable)
• Timing: morning supine, 5 min RMSSD, or wearable nighttime mean (build a 4-week personal baseline)
• What matters: 7-day rolling mean + today's % deviation, not absolute number

How to use:
• Today's HRV > 7-day mean: normal or push (HIIT / heavy lifting)
• Today's HRV within ±10% of 7-day mean: train as planned
• Today's HRV >10% below 7-day mean: Zone 2 only / yoga / rest
• 3–5 consecutive days suppressed: suspect prodrome, overtraining, chronic stress → de-load + investigate

High-evidence HRV-raising interventions:
• Slow breathing 6 br/min (≈ 4s in / 6s out) × 5–10 min/day → measurable short-term gain
• No alcohol (even 1–2 drinks lowers nightly HRV 20–30%)
• Consistent sleep window (±30 min)
• Zone 2 training (> 4 weeks)
• Moderate cold/sauna exposure

What HRV cannot do:
• Diagnose arrhythmia (use ECG)
• Cross-person comparison ("my HRV is higher than hers, so I'm healthier" — meaningless)
• Replace ApoB, BP, CAC, or other hard markers

FEMALE-SPECIFIC NOTE + COMMON MYTHS

The menstrual cycle has a systematic effect on HRV: follicular phase (days 1–14) has higher HRV (parasympathetic-dominant); luteal phase (post-ovulation to next menses) drops HRV by ~10–15% with resting HR up 2–5 bpm (Tenan 2014). This is physiologic, not overtraining. Always interpret HRV trends alongside cycle phase — lower luteal HRV should not trigger de-load. During perimenopause, cycle disruption widens HRV variance; hot flashes and sleep fragmentation cause measurable nightly HRV drops — a useful objective measure of symptom burden. Pregnancy reduces HRV overall (physiologic volume/output changes); has no diagnostic value.

Myth 1: "Higher HRV is always better" — extremely high HRV can be abnormal (hypothyroidism, severe underweight, certain arrhythmias). Trend matters more than absolute.
Myth 2: "HRV is the health gold standard" — it is an auxiliary monitor, not a substitute for BP, ApoB, CAC, and cannot diagnose disease.
Myth 3: "All devices give comparable HRV" — algorithms (frequency- vs time-domain, night mean vs morning spot) differ widely. Track yourself on one device.

THIS WEEK + REFLECTION

THIS WEEK

If you wear a device: export the past 4 weeks of HRV trends and overlay training days / alcohol nights / sleep-short nights — find your personal patterns. No device: do 5 minutes of slow breathing (4s in / 6s out) before bed for 7 days; compare your subjective daytime stress response.

Reflection: HRV turns "body feel" into numbers. Is that sharper self-awareness, or a new anxiety machine? Where do you sit on the data-driven vs body-intuition axis?

📚 Resources

📕 Peter Attia. Outlive: The Science and Art of Longevity. 2023. — Chapters 7–8 ASCVD "Medicine 3.0" integration: CAC, ApoB, Lp(a), BP
🎙 The Drive (Peter Attia) #228 with Allan Sniderman — ApoB & Lp(a); #284 with Ethan Weiss — CAC clinical use; #185 with Andrew Huberman — HRV & autonomic nervous system
🎙 Huberman Lab — "Tools to Improve Cardiovascular Health & Performance" — HRV with hot/cold protocols
📕 Mary Claire Haver. The New Menopause. 2024. — Perimenopausal CV-risk acceleration windows and intervention timing
📄 SPRINT Research Group. Intensive vs Standard BP Control. NEJM. 2015;373:2103-2116.
📄 Kronenberg F, et al. EAS Lp(a) Consensus Statement. Eur Heart J. 2022;43:3925-3946. — Test once in life
📄 Detrano R, et al. CAC for CHD Risk Prediction. NEJM. 2008;358:1336-1345. — MESA
📄 Kamstrup PR, et al. Lp(a) & MI Mendelian Randomization. JAMA. 2009;301:2331-2339.
📄 Thayer JF, et al. HRV and Cardiovascular Risk. Int J Cardiol. 2010;141:122-131.

🧠 Reflections

① Is CAC = 0 a clean bill of health for coronary arteries?

Not quite. CAC reflects calcified plaque. Early soft plaque (lipid pools, non-calcified fibrous plaque) can be entirely invisible, especially under 45. MESA and CONFIRM data show CAC=0 + 5-year event rate <1%, but "5 years" ≠ "lifetime," and acute events often arise from non-calcified, unstable plaque rupture — which is why ApoB, Lp(a), and lifestyle still matter. CCTA (coronary CT angiography) can visualize soft plaque, costs slightly more radiation, and suits CAC=0 individuals with otherwise strong risk factors.

② Lp(a) has no specific drug yet — what's the point of testing?

The point isn't "treat Lp(a)" — it's recalibrating other modifiable factors. Lp(a) 100 mg/dL ≈ 2× CV risk, equivalent to lowering your ApoB ceiling from 80 to 60, your BP target from 120 to 115, and shifting smoking from "advised against" to "must quit." This is the risk-budget mentality — the same lifestyle interventions yield higher marginal benefit in high-Lp(a) individuals. Specific Lp(a)-lowering drugs (pelacarsen, olpasiran) have Phase III readouts in 2025–2026 — testing now puts you in the data pipeline for future therapy access.

③ Is intensive BP control (<120) really good for everyone?

SPRINT excluded diabetics, prior strokes, and dementia patients and used rigorous AOBP (automated office BP, closer to home BP than standard office readings). True office "120" in real-world clinics ≈ SPRINT "130." Side effects of intensive control include hypotensive syncope, falls, transient renal function decline (mostly reversible) — elderly and comorbid populations need individualization. But for healthy middle-aged adults, "I've always been 125/80, no problem" is widely-underestimated cumulative damage — every 10 mmHg SBP reduction is a stable 20% event-rate reduction across ages and baselines.

④ Is HRV data a triumph of self-quantification or new-age anxiety?

Depends on framing. HRV as input (today's HRV is low → de-load, sleep, check for infection) = tool serving decision. HRV as score (HRV low = I'm unhealthy/lazy) = tool enslaving decision. Whoop/Oura UX leans toward the latter — "Recovery 30%" creates anxiety on top of fatigue you already feel. BigCat-style usage: review the trend once per week + at key decision points (pre-race, prodrome, cycle-phase comparison), don't stare daily. When body feel and HRV data disagree, trust the body — HRV is auxiliary.

⑤ How do these four metrics integrate into a single "CV longevity dashboard"?

Structural recommendation: (1) Genetic baseline — Lp(a) once in life + family history; (2) Cumulative pathology — CAC (once at intermediate risk ≥40, recheck ≥60) + carotid US; (3) Active load — BP (weekly home log + annual ABPM) + ApoB (annual); (4) Dynamic recovery — HRV trend + resting HR. The first three set your risk-curve slope (long-term); HRV gauges this week's recovery state (short-term). Putting them on one sheet + annual review is the essence of Attia "Medicine 3.0" — use data to extend healthspan, instead of chasing disease via symptoms.

← Back to Index